RS65914B1 - Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja - Google Patents

Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja

Info

Publication number: RS65914B1
Authority: RS; Serbia
Prior art keywords: phenyl; acetylamino; hydroxy; methyl; compounds
Prior art date: 2017-04-18

Application number

RS20240950A

Other languages

English (en)

Inventor

Marta Maria Cifuentes-Garcia

Maria Cristina Garcia-Paredes

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-04-18

Filing date

2018-04-11

Publication date

2024-10-31

2018-04-11 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2024-10-31 Publication of RS65914B1 publication Critical patent/RS65914B1/sr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)

RS20240950A 2017-04-18 2018-04-11 Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja RS65914B1 (sr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP17382207		2017-04-18
EP21211015.9A EP4039675B1 (en)	2017-04-18	2018-04-11	Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Publications (1)

Publication Number	Publication Date
RS65914B1 true RS65914B1 (sr)	2024-10-31

Family

ID=58606227

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RS20220154A RS62933B1 (sr)	2017-04-18	2018-04-11	Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja
RS20240950A RS65914B1 (sr)	2017-04-18	2018-04-11	Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
RS20220154A RS62933B1 (sr)	2017-04-18	2018-04-11	Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja

Country Status (29)

Country	Link
US (2)	US11655214B2 (sr)
EP (2)	EP3612519B1 (sr)
JP (2)	JP7110232B2 (sr)
KR (2)	KR102575246B1 (sr)
CN (2)	CN117510405A (sr)
AU (2)	AU2018255191B2 (sr)
BR (1)	BR112019021867A2 (sr)
CA (1)	CA3060564A1 (sr)
CO (1)	CO2019012767A2 (sr)
CR (1)	CR20190519A (sr)
CY (1)	CY1125150T1 (sr)
DK (2)	DK4039675T3 (sr)
ES (2)	ES2988739T3 (sr)
FI (1)	FI4039675T3 (sr)
HR (2)	HRP20220263T1 (sr)
HU (2)	HUE068023T2 (sr)
IL (2)	IL270005B (sr)
LT (2)	LT4039675T (sr)
MX (2)	MX2019012428A (sr)
PH (1)	PH12019502363B1 (sr)
PL (2)	PL3612519T3 (sr)
PT (2)	PT4039675T (sr)
RS (2)	RS62933B1 (sr)
SA (1)	SA519410320B1 (sr)
SG (1)	SG11201909680UA (sr)
SI (2)	SI3612519T1 (sr)
SM (2)	SMT202400357T1 (sr)
WO (1)	WO2018194885A1 (sr)
ZA (1)	ZA201906811B (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7110232B2 (ja) *	2017-04-18	2022-08-01	イーライリリーアンドカンパニー	フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物
EP3775171B1 (en)	2018-03-26	2024-01-03	Icahn School of Medicine at Mount Sinai	Methods of treating minimal residual cancer
WO2021041970A1 (en)	2019-08-29	2021-03-04	Hibercell, Inc.	Perk inhibiting imidazolopyrazine compounds
CN114710956A (zh) *	2019-08-29	2022-07-05	希伯塞尔股份有限公司	抑制perk的吡咯并嘧啶化合物
EP4021893A1 (en) *	2019-08-29	2022-07-06	Hibercell, Inc.	Perk inhibiting compounds
WO2021041976A1 (en)	2019-08-29	2021-03-04	Hibercell, Inc.	Perk inhibiting indolinyl compounds
WO2021231782A1 (en) *	2020-05-13	2021-11-18	Hibercell, Inc.	Perk inhibitors for treating viral infections
WO2021231788A1 (en) *	2020-05-13	2021-11-18	Hibercell, Inc.	Perk inhibiting pyrrolopyrimidine compounds to treat viral infections
CN113234029B (zh) *	2021-05-25	2022-03-22	白银康寓信生物科技有限公司	一种2-氨基-3,5-二卤代吡嗪的合成方法
WO2024206890A1 (en) *	2023-03-30	2024-10-03	Hibercell, Inc.	Crystalline forms of (r)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-n-isopropylnicotinamide and methods for using the same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7863444B2 (en)	1997-03-19	2011-01-04	Abbott Laboratories	4-aminopyrrolopyrimidines as kinase inhibitors
AU748884B2 (en)	1997-03-19	2002-06-13	Abbott Gmbh & Co. Kg	Pyrrolo(2,3d)pyrimidines and their use as tyrosine kinase inhibitors
TW200306819A (en) *	2002-01-25	2003-12-01	Vertex Pharma	Indazole compounds useful as protein kinase inhibitors
CA2484209C (en)	2002-05-03	2013-06-11	Exelixis, Inc.	Protein kinase modulators and methods of use
KR101139557B1 (ko)	2003-07-23	2012-04-30	바이엘 파마슈티칼스 코포레이션	질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
PE20070427A1 (es)	2005-08-30	2007-04-21	Novartis Ag	Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
US8211919B2 (en) *	2005-09-02	2012-07-03	Astellas Pharma Inc.	Amide derivatives as rock inhibitors
ES2545760T3 (es)	2008-02-25	2015-09-15	Nestec S.A.	Selección de fármacos para terapia del cáncer de mama utilizando matrices de anticuerpos
WO2010080992A1 (en)	2009-01-09	2010-07-15	The Trustees Of The University Of Pennsylvania	Regulators of the interferon-alpha receptor 1 (ifnar1) chain of the interferon receptor
US8598156B2 (en)	2010-03-25	2013-12-03	Glaxosmithkline Llc	Chemical compounds
EP2986286A1 (en)	2013-04-15	2016-02-24	Universita' Degli Studi di Bari	Galloyl benzamide-based compounds as jnk modulators
WO2015056180A1 (en)	2013-10-15	2015-04-23	Glaxosmithkline Intellectual Property (No.2) Limited	Indoline derivatives as inhibitors of perk
EP3067356B1 (en)	2013-11-08	2018-07-04	ONO Pharmaceutical Co., Ltd.	Pyrrolo pyrimidine derivative
WO2015136463A1 (en)	2014-03-11	2015-09-17	Glaxosmithkline Intellectual Property (No.2) Limited	Chemical compounds acting as perk inhibitors
WO2016004254A1 (en)	2014-07-01	2016-01-07	The Regents Of The University Of California	Combined modulation of ire1
MX2017006366A (es)	2014-11-14	2018-02-01	Nerviano Medical Sciences Srl	Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
GB201508747D0 (en)	2015-05-21	2015-07-01	Univ Edinburgh	Compounds
CN108026102A (zh) *	2015-07-24	2018-05-11	蓝印药品公司	可用于治疗与kit和pdgfr相关的病症的化合物
KR102327917B1 (ko)	2016-07-07	2021-11-17	주식회사 대웅제약	신규한 4-아미노피라졸로[3,4-d]피리미디닐아자바이사이클로 유도체 및 이를 포함하는 약학 조성물
KR20190028540A (ko)	2016-07-20	2019-03-18	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	Perk 억제제로서의 이소퀴놀린 유도체
CN106748989B (zh)	2016-11-14	2020-03-17	西安交通大学	一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用
US20190388426A1 (en)	2017-01-30	2019-12-26	Université de Liège	Perk and ire-1a inhibitors against neurodevelopmental disorders
JP7110232B2 (ja)	2017-04-18	2022-08-01	イーライリリーアンドカンパニー	フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物
JP7304855B2 (ja)	2017-11-14	2023-07-07	ザチルドレンズメディカルセンターコーポレーション	新規イミダゾピリミジン化合物およびそれらの使用
EP3492454A1 (en)	2017-11-30	2019-06-05	Step Pharma S.A.S.	Compounds
EP3775171B1 (en)	2018-03-26	2024-01-03	Icahn School of Medicine at Mount Sinai	Methods of treating minimal residual cancer
AU2019297428C1 (en)	2018-07-06	2023-03-23	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
WO2020070053A1 (en)	2018-10-01	2020-04-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of inhibitors of stress granule formation for targeting the regulation of immune responses

2018
- 2018-04-11 JP JP2019556703A patent/JP7110232B2/ja active Active
- 2018-04-11 EP EP18718570.7A patent/EP3612519B1/en active Active
- 2018-04-11 KR KR1020197033523A patent/KR102575246B1/ko active IP Right Grant
- 2018-04-11 LT LTEP21211015.9T patent/LT4039675T/lt unknown
- 2018-04-11 PL PL18718570T patent/PL3612519T3/pl unknown
- 2018-04-11 CN CN202310753648.5A patent/CN117510405A/zh active Pending
- 2018-04-11 EP EP21211015.9A patent/EP4039675B1/en active Active
- 2018-04-11 BR BR112019021867-0A patent/BR112019021867A2/pt unknown
- 2018-04-11 SI SI201830572T patent/SI3612519T1/sl unknown
- 2018-04-11 HU HUE21211015A patent/HUE068023T2/hu unknown
- 2018-04-11 HU HUE18718570A patent/HUE057745T2/hu unknown
- 2018-04-11 WO PCT/US2018/027005 patent/WO2018194885A1/en active Application Filing
- 2018-04-11 US US16/606,410 patent/US11655214B2/en active Active
- 2018-04-11 AU AU2018255191A patent/AU2018255191B2/en active Active
- 2018-04-11 SI SI201831149T patent/SI4039675T1/sl unknown
- 2018-04-11 PT PT212110159T patent/PT4039675T/pt unknown
- 2018-04-11 SM SM20240357T patent/SMT202400357T1/it unknown
- 2018-04-11 ES ES21211015T patent/ES2988739T3/es active Active
- 2018-04-11 PT PT187185707T patent/PT3612519T/pt unknown
- 2018-04-11 RS RS20220154A patent/RS62933B1/sr unknown
- 2018-04-11 ES ES18718570T patent/ES2906847T3/es active Active
- 2018-04-11 FI FIEP21211015.9T patent/FI4039675T3/fi active
- 2018-04-11 PH PH1/2019/502363A patent/PH12019502363B1/en unknown
- 2018-04-11 LT LTEPPCT/US2018/027005T patent/LT3612519T/lt unknown
- 2018-04-11 KR KR1020237029674A patent/KR20230129627A/ko not_active Application Discontinuation
- 2018-04-11 CN CN201880033126.5A patent/CN110831927B/zh active Active
- 2018-04-11 DK DK21211015.9T patent/DK4039675T3/da active
- 2018-04-11 SG SG11201909680U patent/SG11201909680UA/en unknown
- 2018-04-11 DK DK18718570.7T patent/DK3612519T3/da active
- 2018-04-11 RS RS20240950A patent/RS65914B1/sr unknown
- 2018-04-11 CR CR20190519A patent/CR20190519A/es unknown
- 2018-04-11 PL PL21211015.9T patent/PL4039675T3/pl unknown
- 2018-04-11 HR HRP20220263TT patent/HRP20220263T1/hr unknown
- 2018-04-11 MX MX2019012428A patent/MX2019012428A/es unknown
- 2018-04-11 SM SM20220100T patent/SMT202200100T1/it unknown
- 2018-04-11 HR HRP20241188TT patent/HRP20241188T1/hr unknown
- 2018-04-11 CA CA3060564A patent/CA3060564A1/en active Pending
2019
- 2019-10-16 ZA ZA2019/06811A patent/ZA201906811B/en unknown
- 2019-10-17 IL IL270005A patent/IL270005B/en unknown
- 2019-10-17 MX MX2022001310A patent/MX2022001310A/es unknown
- 2019-10-17 SA SA519410320A patent/SA519410320B1/ar unknown
- 2019-11-15 CO CONC2019/0012767A patent/CO2019012767A2/es unknown
2021
- 2021-12-09 IL IL288822A patent/IL288822B2/en unknown
2022
- 2022-03-01 CY CY20221100173T patent/CY1125150T1/el unknown
- 2022-07-18 AU AU2022206702A patent/AU2022206702B2/en active Active
- 2022-07-20 JP JP2022115300A patent/JP7331212B2/ja active Active
2023
- 2023-04-13 US US18/300,237 patent/US20230373922A1/en active Pending

Also Published As

Publication number	Publication date
ES2906847T3 (es)	2022-04-20
DK4039675T3 (da)	2024-09-02
KR20230129627A (ko)	2023-09-08
MX2022001310A (es)	2022-03-02
JP2022141835A (ja)	2022-09-29
ZA201906811B (en)	2021-01-27
PT4039675T (pt)	2024-09-16
MX2019012428A (es)	2022-01-28
SG11201909680UA (en)	2019-11-28
AU2022206702A1 (en)	2022-08-11
US11655214B2 (en)	2023-05-23
CA3060564A1 (en)	2018-10-25
US20210114985A1 (en)	2021-04-22
HRP20220263T1 (hr)	2022-04-29
EP4039675A1 (en)	2022-08-10
BR112019021867A2 (pt)	2020-05-26
HUE057745T2 (hu)	2022-06-28
AU2018255191B2 (en)	2022-04-21
JP2021517555A (ja)	2021-07-26
FI4039675T3 (fi)	2024-09-10
IL270005B (en)	2022-01-01
RU2019136694A3 (sr)	2021-05-19
KR20190140966A (ko)	2019-12-20
RS62933B1 (sr)	2022-03-31
ES2988739T3 (es)	2024-11-21
CN117510405A (zh)	2024-02-06
WO2018194885A1 (en)	2018-10-25
US20230373922A1 (en)	2023-11-23
SI4039675T1 (sl)	2024-10-30
DK3612519T3 (da)	2022-03-07
HUE068023T2 (hu)	2024-12-28
CY1125150T1 (el)	2023-06-09
PH12019502363B1 (en)	2023-11-15
PT3612519T (pt)	2022-02-22
KR102575246B1 (ko)	2023-09-06
LT3612519T (lt)	2022-03-25
SMT202200100T1 (it)	2022-03-21
PL4039675T3 (pl)	2025-01-07
AU2022206702B2 (en)	2024-04-11
EP4039675B1 (en)	2024-06-12
LT4039675T (lt)	2024-10-10
IL288822B2 (en)	2023-06-01
CN110831927A (zh)	2020-02-21
RU2019136694A (ru)	2021-05-18
CR20190519A (es)	2020-03-06
IL288822A (en)	2022-02-01
PH12019502363A1 (en)	2020-12-07
EP3612519A1 (en)	2020-02-26
SA519410320B1 (ar)	2022-05-08
JP7331212B2 (ja)	2023-08-22
AU2018255191A1 (en)	2019-11-07
PL3612519T3 (pl)	2022-05-02
CN110831927B (zh)	2023-07-14
SI3612519T1 (sl)	2022-04-29
EP3612519B1 (en)	2021-12-01
JP7110232B2 (ja)	2022-08-01
CO2019012767A2 (es)	2020-04-01
SMT202400357T1 (it)	2024-11-15
HRP20241188T1 (hr)	2024-12-06

Publication	Publication Date	Title
GB201708456D0 (en)	2017-07-12	Senolytic compounds
GB201700814D0 (en)	2017-03-01	Compounds
GB201704327D0 (en)	2017-05-03	Compounds
IL288822A (en)	2022-02-01	Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
GB201704325D0 (en)	2017-05-03	Compounds
GB201715342D0 (en)	2017-11-08	Compounds
GB201713962D0 (en)	2017-10-18	Compounds
GB201716871D0 (en)	2017-11-29	Compounds
IL292485B2 (en)	2023-09-01	Pyridylpyridone compounds
GB201717051D0 (en)	2017-11-29	Compounds
GB201707938D0 (en)	2017-06-28	Compounds
GB201706162D0 (en)	2017-05-31	Compounds
GB201702221D0 (en)	2017-03-29	Compounds
GB201716369D0 (en)	2017-11-22	Compounds
GB201715786D0 (en)	2017-11-15	Compounds
GB201703282D0 (en)	2017-04-12	Compounds
GB201721330D0 (en)	2018-01-31	Compounds
GB201721331D0 (en)	2018-01-31	Compounds
GB201721326D0 (en)	2018-01-31	Compounds
GB201720495D0 (en)	2018-01-24	ß-lactone compounds
GB201720064D0 (en)	2018-01-17	Compounds
GB201719261D0 (en)	2018-01-03	Compounds
GB201717718D0 (en)	2017-12-13	Compounds
GB201717050D0 (en)	2017-11-29	Compounds
GB201716688D0 (en)	2017-11-29	Compounds